9:33 AM
 | 
Apr 20, 2018
 |  BC Week In Review  |  Company News  |  Deals

Highmark, AstraZeneca in outcomes-based Symbicort contract

Blue Cross Blue Shield's Highmark Inc. affiliate and AstraZeneca plc (LSE:AZN; NYSE:AZN) entered into an outcomes-based contract for Symbicort budesonide/formoterol to treat symptoms in chronic obstructive pulmonary disease (COPD) and...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >